US Edition
Elevation Oncology’s (ELEV) “Market Perform” Rating Reaffirmed at William Blair
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
William Blair Reaffirms “Market Perform” Rating for Elevation Oncology (NASDAQ:ELEV)
Elevation Oncology (NASDAQ:ELEV – Get Free Report)‘s stock had its “market perform” rating reiterated by equities research analysts at William Blair in a report released on Monday,Benzinga reports. Several other research firms have also recently commented on ELEV. Leerink Partners cut Elevation Oncology from an “outperform” rating to a “market perform” rating and reduced their […]
Elevation Oncology’s (ELEV) “Market Perform” Rating Reaffirmed at William Blair
Elevation Oncology (NASDAQ:ELEV – Get Free Report)‘s stock had its “market perform” rating reissued by research analysts at William Blair in a note issued to investors on Monday,Benzinga reports. A number of other analysts have also recently weighed in on the stock. Leerink Partners cut shares of Elevation Oncology from an “outperform” rating to a […]
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
